In the ever-changing health landscape, sometimes methods and medicines are vilified for a time, only to emerge anew, bolstered by science. Such is the case with psychedelics, those potent mind-manifesting drugs that caused a furor in the 1960s and early 1970s. For decades since the Timothy Leary-era of tripping and dropping out, this class of drugs was in deep-freeze, with no studies or funding available. But a thaw in thinking, and a number of studies have emerged showing benefits of this once shunned category.
According to a newly published study of 135,000 Americans, the use of psychedelics, including LSD, psilocybin and mescaline, is not linked to any increased risk of suicide, suicidal thoughts, or various forms of psychological stress. The study, published in the March 5 edition of the Journal of Psychopharmacology, is entitled “Psychedelics not linked to mental health problems or suicidal behavior: A population study.”